DEF: enVVeno Medical Awaits VenoValve FDA Appeal Decision

enVVeno Medical Corporation is awaiting a critical FDA decision on its VenoValve appeal by year-end 2025, while also seeking shareholder approval for a new 2025 Equity Incentive Plan and director elections.

Summary

• An appeal to overturn the 'not-approvable' decision for the VenoValve in the United States is pending before the U.S. Food and Drug Administration (FDA).
• The formal request for the supervisory appeal was filed on September 18, 2025, and the company expects to hear from the FDA by the end of 2025.
• An in-person meeting with the FDA was completed, including the Director of the Center for Devices and Radiological Health, a patient from the SAVVE study, and a primary investigator.
• The company presented evidence for an alternative effectiveness pathway for VenoValve, supported by data already collected in the SAVVE study.
• Clarity from the FDA is being awaited prior to filing the enVVe IDE application, which is the company's next-generation transcatheter replacement venous valve.
• Strong support from the physician and patient communities for the VenoValve and the company continues.
• The Annual Meeting of Stockholders is scheduled for December 11, 2025, at 9:00 AM PST, to be held virtually.
• Proposals for the annual meeting include the election of Matthew M. Jenusaitis and Robert A. Berman as Class II Directors, an advisory vote on named executive officer compensation, ratification of CBIZ CPAs P.C. as the independent auditor for fiscal year 2025, and approval of the enVVeno Medical Corporation 2025 Equity Incentive Plan.
• The Board of Directors unanimously recommends a vote FOR all proposals.
• There were 20,216,176 shares of Common Stock outstanding on the Record Date of October 17, 2025.
• Net Loss for the fiscal year ended December 31, 2024, was $(21,819,000), compared to $(23,516,000) in 2023 and $(24,669,000) in 2022.
• Total Shareholder Return (TSR) was $45.83 for 2024, down from $78.00 in 2023 and $77.39 in 2022 (based on a $100 fixed investment from end of 2021).

Sentiment

Score: 4

Explanation: The company faces significant regulatory hurdles with its flagship product, VenoValve, having received a 'not-approvable' decision from the FDA. This uncertainty is also delaying the next-generation product, enVVe. While management is actively appealing and highlights patient support, the core business is stalled by regulatory challenges, reflected in declining TSR. The decrease in net loss is a minor positive in the context of major product approval issues.

Positives

• Completed an in-person meeting with the FDA regarding the VenoValve appeal, which included high-level FDA officials, a patient, and an investigator, providing an opportunity to present the product's benefits and context for adverse events.
• Presented evidence for an alternative effectiveness pathway for VenoValve using existing SAVVE study data, demonstrating proactive engagement with regulatory challenges.
• Continued strong support from physician and patient communities for VenoValve and the company, indicating market need and clinical interest.
• Net loss decreased from $(23,516,000) in 2023 to $(21,819,000) in 2024, showing a slight improvement in financial performance.
• The proposed 2025 Equity Incentive Plan aims to attract, retain, and motivate key personnel, which is crucial for long-term growth and innovation.

Negatives

• The VenoValve received a 'not-approvable' decision from the FDA, posing a significant regulatory hurdle for market entry.
• There are no established industry or regulatory standards for replacement venous valves, requiring the company and FDA to establish a new, potentially complex, regulatory pathway.
• The filing of the enVVe IDE application, for the next-generation transcatheter valve, is delayed pending clarity from the FDA on the VenoValve appeal.
• Total Shareholder Return (TSR) significantly declined from $78.00 in 2023 to $45.83 in 2024, indicating poor stock performance over the past year.

Risks

• Uncertainty regarding the outcome of the FDA appeal for VenoValve, which could prevent market access for the company's primary product.
• The absence of established industry or regulatory standards for replacement venous valves creates a complex and potentially lengthy process for regulatory approval.
• Delays in the development and regulatory submission of enVVe, the next-generation product, due to the ongoing VenoValve appeal, could impact future revenue streams.
• Reliance on FDA approval for the commercialization of VenoValve and enVVe, which are critical for addressing the 2.5 to 3.5 million patients suffering from deep venous CVI.
• Potential for dilution of shareholder value if the 2025 Equity Incentive Plan is approved and a significant number of new shares are issued.
• The company's ability to attract and retain qualified personnel may be impacted by ongoing regulatory uncertainties and stock performance.

Future Outlook

The company is awaiting clarity from the FDA on a path forward for both VenoValve and enVVe, and remains committed to bringing relief to the 2.5 to 3.5 million patients suffering from deep venous CVI in the U.S. who currently lack effective treatment options. The proposed 2025 Equity Incentive Plan is intended to enhance the company's ability to attract, retain, and motivate individuals who contribute to its success.

Management Comments

• Our appeal to over-turn the not-approvable decision to market and sell the VenoValve in the United States is pending before the U.S. Food and Drug Administration (FDA).
• We are on track to hear from the FDA about this stage of the appeal process by the end of 2025.
• The FDA meeting provided us with the opportunity to put the major adverse events—those tied to the SAVVE study’s safety endpoints—into the proper context.
• It also allowed us to re-emphasize the multiple physicianand patient-reported clinical benefits that comprise the totality of the evidence from the study, supported by firsthand perspectives shared by both the SAVVE study patient and investigator in attendance.
• Because there are no established industry or regulatory standards to determine the effectiveness for a replacement venous valve, it is necessary for the Sponsor and the Agency to establish a new regulatory pathway for VenoValve effectiveness.
• Although the subject of this appeal and the FDA meeting is specific to the VenoValve, the appeal does also have implications for enVVe, our next generation transcatheter replacement venous valve, and as a result, we are waiting for clarity from the FDA prior to filing the enVVe IDE application.
• Support from the physician and patient communities for the VenoValve and our company continues to be strong.
• We look forward to receiving clarity from the FDA on a path forward for both the VenoValve and enVVe and remain committed to bringing relief to the 2.5 to 3.5 million patients suffering from deep venous CVI in the U.S. and who have no effective treatment options.

Industry Context

The company operates in the medical device sector, specifically addressing chronic venous insufficiency (CVI) with its VenoValve and next-generation enVVe. The challenge of establishing a new regulatory pathway for replacement venous valves highlights the innovative nature of their products but also the significant regulatory hurdles in a field lacking established standards. The target market of 2.5 to 3.5 million patients in the U.S. with no effective treatment options indicates a substantial unmet medical need, positioning the company to potentially capture a significant market share if regulatory approvals are secured.

Comparison to Industry Standards

• There are no established industry or regulatory standards to determine the effectiveness for a replacement venous valve, necessitating the company and the FDA to establish a new regulatory pathway for VenoValve effectiveness.
• The company is addressing a significant unmet medical need for 2.5 to 3.5 million patients suffering from deep venous CVI in the U.S. who currently have no effective treatment options, indicating a potentially large market opportunity if regulatory hurdles are overcome.

Management Changes

Corporate Governance

Legal Proceedings

• An appeal to overturn the 'not-approvable' decision for VenoValve is pending before the U.S. Food and Drug Administration (FDA).

Related Party Transactions

• Perceptive Life Sciences Master Fund, Ltd., a holder of greater than 5% of common stock, participated in a financing on October 6, 2023, purchasing pre-funded warrants and Tranche A and B Warrants.

Stakeholder Impact

• Shareholders are directly impacted by the outcome of the FDA appeal for VenoValve, the delay in enVVe, and the proposed 2025 Equity Incentive Plan (potential dilution). The declining Total Shareholder Return (TSR) reflects market apprehension.
• Patients suffering from deep venous CVI in the U.S. are awaiting effective treatment options, making the VenoValve and enVVe approvals critical for their health and quality of life.
• Employees and management are impacted by the 2025 Equity Incentive Plan, designed to attract, retain, and motivate them. Regulatory uncertainty could affect morale and future career prospects.
• The FDA is engaged in a collaborative dialogue with the company to establish a new regulatory pathway for venous valve effectiveness, highlighting the agency's role in bringing innovative treatments to market.

Next Steps

• Await FDA decision on VenoValve supervisory appeal by the end of 2025.
• File enVVe IDE application after receiving clarity from the FDA on VenoValve.
• Hold virtual Annual Meeting of Stockholders on December 11, 2025.
• Elect Matthew M. Jenusaitis and Robert A. Berman as Class II Directors.
• Approve, on a non-binding, advisory basis, the compensation of named executive officers.
• Ratify the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2025.
• Approve the adoption of the enVVeno Medical Corporation 2025 Equity Incentive Plan.
• The company intends to file a registration statement on Form S-8 covering shares issuable under the 2025 Plan.

Key Dates

Recommendation

The company is at a critical juncture with its VenoValve product facing a 'not-approvable' FDA decision and a pending appeal. While the appeal process is active and management is presenting alternative pathways, the outcome remains highly uncertain and will significantly impact the company's future. The delay in the next-generation enVVe product further compounds this uncertainty. The declining Total Shareholder Return (TSR) reflects market apprehension. An investor should 'hold' to await the FDA's decision by year-end 2025, as this will be the primary driver of the stock's near-term performance. Without clarity on the regulatory path, a 'buy' would be too speculative, and a 'sell' might be premature given the ongoing appeal and potential for a positive resolution.

Keywords

Medical device, FDA appeal, VenoValve, enVVe, Chronic venous insufficiency, CVI, SAVVE study, Regulatory pathway, Equity incentive plan, Corporate governance, Proxy statement, Shareholder meeting, Executive compensation, Auditor change